A radioimmunotherapy trial was also performed in prostate cancer with a bispecific anti-TROP-2 (expressed by prostate cancer cells) and anti-HSG, called TF12, and showed a higher median survival following 2 or 3 cycles compared to controls (>150 vs. 76 days) [32]. This evidence concerns the gene TACSTD2 and prostate carcinoma.